NeuroMetrix announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,474,898. The patent covers key technology that enables safe delivery of Quell® therapy for chronic pain while the user is sleeping.
Over 80% of chronic pain sufferers report low quality sleep, which then further exacerbates pain. Quell is the only high intensity transcutaneous electrical nerve stimulator cleared by the FDA for use while sleeping.
The claims cover a novel approach to using skin-electrode impedance measurements to continually monitor the Quell electrode array contact area.
If the area drops to a critical level due to unintended electrode peeling, the device automatically shuts off electrical stimulation thereby providing a safety mechanism while the user is sleeping and unaware.
This patent further establishes and differentiates the leading technology and clinical benefits of Quell Wearable Pain Relief Technology™.
Quell is designed for millions of people suffering from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping.
It has been cleared by the FDA for treatment of chronic pain without a prescription. In a recent study, 81% of Quell users reported an improvement in their chronic pain.